About Novan (NASDAQ:NOVN)
Novan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company's product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology. The company has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NOVN
CUSIPN/A
Phone919-485-8080
Debt
Debt-to-Equity Ratio-0.01%
Current Ratio0.44%
Quick Ratio0.44%
Price-To-Earnings
Trailing P/E Ratio-1.35
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.14 million
Price / Sales38.09
Cash FlowN/A
Price / CashN/A
Book Value($0.09) per share
Price / Book-34.78
Profitability
EPS (Most Recent Fiscal Year)($2.32)
Net Income$-37,120,000.00
Net Margins-1,727.97%
Return on Equity-419.00%
Return on Assets-109.02%
Miscellaneous
Employees59
Outstanding Shares26,040,000
Novan (NASDAQ:NOVN) Frequently Asked Questions
What is Novan's stock symbol?
Novan trades on the NASDAQ under the ticker symbol "NOVN."
How were Novan's earnings last quarter?
Novan (NASDAQ:NOVN) announced its quarterly earnings data on Friday, May, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.24. The company had revenue of $0.10 million for the quarter, compared to analysts' expectations of $10.80 million. Novan had a negative net margin of 1,727.97% and a negative return on equity of 419.00%. View Novan's Earnings History.
When is Novan's next earnings date?
What price target have analysts set for NOVN?
2 analysts have issued 1 year price objectives for Novan's stock. Their predictions range from $6.00 to $6.00. On average, they anticipate Novan's share price to reach $6.00 in the next twelve months. View Analyst Ratings for Novan.
Who are some of Novan's key competitors?
Some companies that are related to Novan include Tetraphase Pharmaceuticals (TTPH), Acer Therapeutics (ACER), Zynerba Pharmaceuticals (ZYNE), Aldeyra Therapeutics (ALDX), BioXcel Therapeutics (BTAI), Galectin Therapeutics (GALT), Sierra Oncology (SRRA), Affimed (AFMD), Aeglea Bio Therapeutics (AGLE), BioDelivery Sciences International (BDSI), Adamis Pharmaceuticals (ADMP), Checkpoint Therapeutics (CKPT), Bellerophon Therapeutics (BLPH), AcelRx Pharmaceuticals (ACRX), Axovant Sciences (AXON), ProQR Therapeutics (PRQR), OncoMed Pharmaceuticals (OMED) and Trevena (TRVN).
Who are Novan's key executives?
Novan's management team includes the folowing people:
- Mr. Robert Alexander Ingram, Exec. Chairman (Age 76)
- Mr. G. Kelly Martin, Interim CEO & Director (Age 59)
- Dr. Nathan Stasko Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
- Mr. Jeff N. Hunter, Interim CFO, Principal Financial & Accounting Officer and Company Sec. (Age 61)
- Mr. Sean Andrews, Sr. Director of Investor Relations
When did Novan IPO?
(NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has Novan been receiving favorable news coverage?
News articles about NOVN stock have trended somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novan earned a news impact score of 0.14 on Accern's scale. They also assigned media coverage about the company an impact score of 46.12 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Novan?
Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novan's stock price today?
One share of NOVN stock can currently be purchased for approximately $3.13.
How big of a company is Novan?
Novan has a market capitalization of $81.50 million and generates $2.14 million in revenue each year. The company earns $-37,120,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Novan employs 59 workers across the globe.
How can I contact Novan?
Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]
MarketBeat Community Rating for Novan (NOVN)
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Novan (NASDAQ:NOVN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Novan in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 91.69%. The high price target for NOVN is $6.00 and the low price target for NOVN is $6.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.00 | $8.50 | $8.50 | $8.50 |
| Price Target Upside: | 91.69% upside | 57.41% upside | 57.41% upside | 57.41% upside |
Novan (NASDAQ:NOVN) Consensus Price Target History
Novan (NASDAQ:NOVN) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Novan (NASDAQ:NOVN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Novan (NASDAQ NOVN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.72%
Institutional Ownership Percentage: 3.20%
Novan (NASDAQ NOVN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/29/2017 | Robert Alexander Ingram | Director | Buy | 12,000 | $4.57 | $54,840.00 | 61,312 |  |
| 8/23/2017 | John W Palmour | Director | Buy | 12,000 | $3.99 | $47,880.00 | 253,568 | |
| 9/26/2016 | Life Sciences Holdings L Malin | Major Shareholder | Buy | 800,000 | $11.00 | $8,800,000.00 | | |
(Data available from 1/1/2013 forward)
Novan (NASDAQ NOVN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Novan's (NOVN) Buy Rating Reiterated at Piper Jaffray
www.americanbankingnews.com - April 13 at 6:01 PM |
 | Same as the old boss — Novan makes interim CEO permanent
finance.yahoo.com - April 13 at 10:09 AM |
| Novan (NOVN) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 12 at 9:35 PM |
 | Novan CEO drops interim label
seekingalpha.com - April 12 at 10:38 AM |
| Novan Inc (NASDAQ:NOVN): Poised For Long-Term Success?
finance.yahoo.com - April 11 at 10:22 AM |
| Cramer: We got too negative on Friday—there's always a be...
finance.yahoo.com - April 10 at 10:07 AM |
| Cramer: There's always a better time to sell
finance.yahoo.com - April 10 at 10:07 AM |
| Novan (NOVN) Lifted to Sell at ValuEngine
www.americanbankingnews.com - April 3 at 11:11 AM |
| Novartis CEO on Alcon and Sandoz
finance.yahoo.com - March 27 at 10:09 AM |
| Novartis expands alliance with Science 37 to advance virtual clinical trials program
finance.yahoo.com - March 7 at 9:47 AM |
| Novartis' Xolair® recommended in new global chronic urticaria guideline
finance.yahoo.com - March 6 at 9:33 AM |
| Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
finance.yahoo.com - March 2 at 9:33 AM |
| Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
finance.yahoo.com - March 1 at 9:22 AM |
| Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
finance.yahoo.com - February 22 at 9:28 AM |
| Dr. Eugene Sun Appointed to Novan Board of Directors
finance.yahoo.com - February 21 at 9:52 AM |
| Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
finance.yahoo.com - February 16 at 4:26 PM |
| Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
finance.yahoo.com - February 16 at 4:26 PM |
| Novan Inc (NOVN) Expected to Post Earnings of -$0.55 Per Share
www.americanbankingnews.com - February 15 at 5:08 PM |
| Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
finance.yahoo.com - February 8 at 9:03 AM |
| SAS founder Goodnight's investment firm becomes Novan's largest stockholder
finance.yahoo.com - January 30 at 4:37 PM |
| 2 Novan execs out as company pushes to broaden focus
finance.yahoo.com - January 25 at 4:34 PM |
| Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
finance.yahoo.com - January 25 at 4:34 PM |
| Trading GE after earnings. Plus, the trade on Kroger & No...
finance.yahoo.com - January 24 at 4:55 PM |
| NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
finance.yahoo.com - January 24 at 4:55 PM |
| Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
finance.yahoo.com - January 24 at 4:55 PM |
 | Novan (NOVN) Prices 10M Share Common Offering at $4.66/Sh
www.streetinsider.com - January 6 at 9:33 AM |
| Novan looks to raise $38M in public offering
finance.yahoo.com - January 5 at 5:04 PM |
| Novan (NOVN) Plans Common Stock Offering
www.streetinsider.com - January 5 at 9:37 AM |
| Novan Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - January 4 at 5:19 PM |
| DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018
finance.yahoo.com - January 2 at 6:40 PM |
| Novan (NOVN) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - January 1 at 3:10 PM |
 | NOVAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit ...
www.businesswire.com - December 31 at 9:20 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline – NOVN
finance.yahoo.com - December 23 at 7:37 PM |
| Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
finance.yahoo.com - December 22 at 9:17 PM |
 | Glancy Prongay & Murray LLP Announces the...
www.benzinga.com - December 21 at 9:31 AM |
| NOVN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - December 18 at 5:18 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018
finance.yahoo.com - December 18 at 5:18 PM |
| NOVN INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Novan, Inc. Investors
finance.yahoo.com - December 18 at 5:18 PM |
| Lawsuit for investors in NASDAQ:NOVN shares against Novan Inc announced by Shareholders Foundation
finance.yahoo.com - December 18 at 9:50 AM |
| Scott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline of January 2
finance.yahoo.com - December 14 at 5:50 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - NOVN
finance.yahoo.com - December 14 at 9:39 AM |
| CORRECTING and REPLACING Robbins Arroyo LLP: Novan, Inc. (NOVN) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - December 11 at 5:29 PM |
| Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
finance.yahoo.com - December 10 at 5:30 PM |
| Stocks tread lower, Bitcoin surges to record high
finance.yahoo.com - December 8 at 9:32 AM |
| The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN)
finance.yahoo.com - December 7 at 5:43 PM |
| Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
finance.yahoo.com - December 6 at 5:18 PM |
| Stocks start in the green despite major tax bill concerns
finance.yahoo.com - December 6 at 9:41 AM |
| IMPORTANT NOVAN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina against Novan, Inc.
finance.yahoo.com - December 5 at 5:14 PM |
| Novan (NOVN) Reports First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414
www.streetinsider.com - December 5 at 10:14 AM |
| NOVN EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - December 4 at 5:16 PM |
Novan (NASDAQ:NOVN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Novan (NASDAQ:NOVN) Income Statement, Balance Sheet and Cash Flow Statement
Novan (NASDAQ NOVN) Stock Chart for Saturday, April, 21, 2018
Loading chart…
